000148298 001__ 148298
000148298 005__ 20240312151045.0
000148298 0247_ $$2doi$$a10.1016/j.prp.2019.152728
000148298 0247_ $$2pmid$$apmid:31784096
000148298 0247_ $$2ISSN$$a0344-0338
000148298 0247_ $$2ISSN$$a1618-0631
000148298 0247_ $$2altmetric$$aaltmetric:71489195
000148298 037__ $$aDKFZ-2019-02862
000148298 041__ $$aeng
000148298 082__ $$a610
000148298 1001_ $$aBraczynski, Anne K$$b0
000148298 245__ $$aHigh density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma.
000148298 260__ $$aMünchen$$bElsevier$$c2020
000148298 3367_ $$2DRIVER$$aarticle
000148298 3367_ $$2DataCite$$aOutput Types/Journal article
000148298 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710252606_32555
000148298 3367_ $$2BibTeX$$aARTICLE
000148298 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148298 3367_ $$00$$2EndNote$$aJournal Article
000148298 500__ $$aVolume 216, Issue 1, January 2020, 152728
000148298 520__ $$aMGMT promoter methylation status is an important biomarker predicting survival and response to chemotherapy in patients suffering from glioblastoma. Since new diagnostic methods such as methylome-based classification of brain tumors are more and more frequently performed, we aimed at comparing the suitability of calculating the MGMT promoter methylation status in a quantitative manner from the methylome profiling as compared to the classic gold standard assessment by PCR.Our cohort consisted of 39 cases diagnosed as 'glioblastoma, IDH-wildtype' of which the MGMT promoter methylation status was analyzed with both methylation-specific PCR and high density DNA methylation array using the STP-27 algorithm. Contradictory results were validated by pyrosequencing.The inter-method reliability reached 77% (kappa-coefficient: 0.58) when also cases with an inconclusive result in one or the other method were taken into account. When only cases with conclusive results in both methods were considered, a very high inter-method reliability of 91% (kappa-coefficient: 0.86) could be achieved. For 'methylated' cases, no contradictory results were obtained. For the remaining two cases with discrepant results subsequent pyrosequencing analyses spoke in favor of each previously applied method once.In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
000148298 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000148298 588__ $$aDataset connected to CrossRef, PubMed,
000148298 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b1$$udkfz
000148298 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b2$$udkfz
000148298 7001_ $$aSchittenhelm, Jens$$b3
000148298 7001_ $$0P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aStichel, Damian$$b4$$udkfz
000148298 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b5$$udkfz
000148298 7001_ $$0P:(DE-He78)b15b56a6ed37417d476470c60c0140ff$$aHarter, Patrick$$b6
000148298 7001_ $$aMittelbronn, Michel$$b7
000148298 773__ $$0PERI:(DE-600)2039756-2$$a10.1016/j.prp.2019.152728$$gp. 152728 -$$n1$$p152728$$tPathology, research and practice$$v216$$x0344-0338$$y2020
000148298 909CO $$ooai:inrepo02.dkfz.de:148298$$pVDB
000148298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000148298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000148298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000148298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000148298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b15b56a6ed37417d476470c60c0140ff$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000148298 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000148298 9141_ $$y2020
000148298 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148298 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000148298 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPATHOL RES PRACT : 2017
000148298 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148298 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000148298 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000148298 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148298 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000148298 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148298 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148298 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000148298 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000148298 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000148298 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK Koordinierungsstelle Dresden$$x0
000148298 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x1
000148298 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000148298 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x3
000148298 980__ $$ajournal
000148298 980__ $$aVDB
000148298 980__ $$aI:(DE-He78)DD01-20160331
000148298 980__ $$aI:(DE-He78)B360-20160331
000148298 980__ $$aI:(DE-He78)B300-20160331
000148298 980__ $$aI:(DE-He78)BE01-20160331
000148298 980__ $$aUNRESTRICTED